A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

J. Glaspy, J. Singh Jadeja, G. Justice, J. Kessler, D. Richards, Lee Schwartzberg, J. Rigas, D. Kuter, D. Harmon, D. Prow, G. Demetri, D. Gordon, J. Arseneau, A. Saven, H. Hynes, R. Boccia, J. O'Byrne, A. B. Colowick

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life, rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg-1 wk-1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg-1 wk-1 cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl-1 respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing.

Original languageEnglish (US)
Pages (from-to)17-23
Number of pages7
JournalBritish Journal of Cancer
Volume84
Issue numberSUPPL. 1
DOIs
StatePublished - May 29 2001

Fingerprint

Anemia
Safety
Drug Therapy
Therapeutics
Erythropoietin
Hemoglobins
Antibody Formation
Darbepoetin alfa
Erythropoiesis
N-Acetylneuraminic Acid
Chronic Kidney Failure
Half-Life
Appointments and Schedules
Physicians

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. / Glaspy, J.; Jadeja, J. Singh; Justice, G.; Kessler, J.; Richards, D.; Schwartzberg, Lee; Rigas, J.; Kuter, D.; Harmon, D.; Prow, D.; Demetri, G.; Gordon, D.; Arseneau, J.; Saven, A.; Hynes, H.; Boccia, R.; O'Byrne, J.; Colowick, A. B.

In: British Journal of Cancer, Vol. 84, No. SUPPL. 1, 29.05.2001, p. 17-23.

Research output: Contribution to journalArticle

Glaspy, J, Jadeja, JS, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Rigas, J, Kuter, D, Harmon, D, Prow, D, Demetri, G, Gordon, D, Arseneau, J, Saven, A, Hynes, H, Boccia, R, O'Byrne, J & Colowick, AB 2001, 'A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy', British Journal of Cancer, vol. 84, no. SUPPL. 1, pp. 17-23. https://doi.org/10.1054/bjoc.2000.1754
Glaspy, J. ; Jadeja, J. Singh ; Justice, G. ; Kessler, J. ; Richards, D. ; Schwartzberg, Lee ; Rigas, J. ; Kuter, D. ; Harmon, D. ; Prow, D. ; Demetri, G. ; Gordon, D. ; Arseneau, J. ; Saven, A. ; Hynes, H. ; Boccia, R. ; O'Byrne, J. ; Colowick, A. B. / A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. In: British Journal of Cancer. 2001 ; Vol. 84, No. SUPPL. 1. pp. 17-23.
@article{18dcc08ced124ee29c8fcad68313c126,
title = "A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy",
abstract = "Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life, rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg-1 wk-1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg-1 wk-1 cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl-1 respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing.",
author = "J. Glaspy and Jadeja, {J. Singh} and G. Justice and J. Kessler and D. Richards and Lee Schwartzberg and J. Rigas and D. Kuter and D. Harmon and D. Prow and G. Demetri and D. Gordon and J. Arseneau and A. Saven and H. Hynes and R. Boccia and J. O'Byrne and Colowick, {A. B.}",
year = "2001",
month = "5",
day = "29",
doi = "10.1054/bjoc.2000.1754",
language = "English (US)",
volume = "84",
pages = "17--23",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

AU - Glaspy, J.

AU - Jadeja, J. Singh

AU - Justice, G.

AU - Kessler, J.

AU - Richards, D.

AU - Schwartzberg, Lee

AU - Rigas, J.

AU - Kuter, D.

AU - Harmon, D.

AU - Prow, D.

AU - Demetri, G.

AU - Gordon, D.

AU - Arseneau, J.

AU - Saven, A.

AU - Hynes, H.

AU - Boccia, R.

AU - O'Byrne, J.

AU - Colowick, A. B.

PY - 2001/5/29

Y1 - 2001/5/29

N2 - Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life, rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg-1 wk-1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg-1 wk-1 cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl-1 respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing.

AB - Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life, rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg-1 wk-1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose-response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg-1 wk-1 cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl-1 respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=0035021354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035021354&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1754

DO - 10.1054/bjoc.2000.1754

M3 - Article

C2 - 11308270

AN - SCOPUS:0035021354

VL - 84

SP - 17

EP - 23

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - SUPPL. 1

ER -